Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 693.

https://doi.org/10.1182/blood-2018-99-114169

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy Stark, MAS, Farrukh T. Awan, MD MS, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Thomas Whitlow, BA, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, MBA

Blood (2017) 130 (Supplement 1): 431.

https://doi.org/10.1182/blood.V130.Suppl_1.431.431

Published: 2017

Journal Articles

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Kerry A. Rogers, MD, Mousa Luay, MD, Qiuhong Zhao, MS, Tracy Wiczer, PharmD, Lauren Levine, PharmD, El Boghdadly Zeinab, MBBCh, James S. Blachly, MD, John C. Byrd, MD, Tomas Guerrero, MD, Jeffrey A. Jones, MD MPH, MBA, Shindiapina Polina, MD PhD, Audrey Sigmund, MD, Matthew Sullivan, MD, Farrukh T. Awan, MD MS, Jennifer A. Woyach, MD

Blood (2017) 130 (Supplement 1): 830.

https://doi.org/10.1182/blood.V130.Suppl_1.830.830

Published: 2017

Journal Articles

Analysis of Healthcare Provider Practice Patterns from Individual Patient Cases Entered into an Online Treatment Decision Tool for Chronic Lymphocytic Leukemia (CLL)

Kristen M Rosenthal, PhD, Farrukh T. Awan, MD MS, Steven Coutre, MD, Jeffrey A. Jones, MD MPH, MBA, Jeffrey P. Sharman, MD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD

Blood (2017) 130 (Supplement 1): 5614.

https://doi.org/10.1182/blood.V130.Suppl_1.5614.5614

Published: 2017

Journal Articles

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Kerry A. Rogers, MD, Ying Huang, MA, MS, Emily Dotson, PharmD, Jordan Lundberg, PharmD, Leslie Andritsos, MD, Farrukh T. Awan, MD MS, Jeffrey A. Jones, MD MPH, MBA, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 5345.

https://doi.org/10.1182/blood.V130.Suppl_1.5345.5345

Published: 2017

Journal Articles

Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A. Jones, MD MPH, Jennifer Woyach, MD, Farrukh T. Awan, Kami J. Maddocks, MD, Thomas Whitlow, BA, Amy S Ruppert, MAS, John C. Byrd, MD

Blood (2016) 128 (22): 639.

https://doi.org/10.1182/blood.V128.22.639.639

Published: 2016

Journal Articles

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Jeffrey A. Jones, MD MPH, Amy J. Johnson, PhD, Farrukh T. Awan, Quihong Zhao, MAS, Natarajan Muthusamy, DVM, PhD, Kami J. Maddocks, MD, Leslie A. Andritsos, MD, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Gerard Lozanski, MD, Nyla A. Heerema, PhD, Cathy Brookfield, BSN, Amy S Ruppert, MAS, John C. Byrd, MD

Blood (2016) 128 (22): 4388.

https://doi.org/10.1182/blood.V128.22.4388.4388

Published: 2016

Journal Articles

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Galena Salem, MD, Deborah M. Stephens, DO, Leslie A. Andritsos, MD, Farrukh T. Awan, MD MS, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, Jeffrey A. Jones, MD MPH

Blood (2015) 126 (23): 2951.

https://doi.org/10.1182/blood.V126.23.2951.2951

Published: 2015

Journal Articles

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh Awan, MD MS, Jeffrey A. Jones, MD MPH, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2953.

https://doi.org/10.1182/blood.V126.23.2953.2953

Published: 2015

Journal Articles

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Blood (2015) 126 (23): 833.

https://doi.org/10.1182/blood.V126.23.833.833

Published: 2015

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

Journal Articles

Assessment Of Hypersensitivity Reactions and Feasibility Of a 60 Minute Rapid Infusion Rituximab Protocol At a Comprehensive Cancer Center

Emily Dotson, PharmD, BCOP, Brooke Crawford, PharmD, BCOP, Gary Phillips, MAS, Jeffrey A. Jones, MD, MPH

Blood (2013) 122 (21): 2985.

https://doi.org/10.1182/blood.V122.21.2985.2985

Published: 2013

Journal Articles

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Emily M. McWilliams, B.S., Carolyn Cheney, B.S, Jeffrey A. Jones, MD, MPH, Joseph M. M. Flynn, DO, MPH, Kami Maddocks, MD, Leslie A. Andritsos, MD, Heather Huet, PhD, Hermann Gram, Ph.D., Johan Baeck, MD, Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2013) 122 (21): 4185.

https://doi.org/10.1182/blood.V122.21.4185.4185

Published: 2013

Journal Articles

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Deborah M Stephens, DO, Amy Stark, MAS, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Susan O'Brien, MD, Michael J. Keating, MD, Natarajan Muthusamy, DVM, Ph.D, Lynne V. Abruzzo, MD, PhD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4128.

https://doi.org/10.1182/blood.V122.21.4128.4128

Published: 2013

Journal Articles

Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)

Nyla A. Heerema, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy S. Ruppert, MAS, Leslie A Andritsos, MD, Michael R. Grever, MD, Jeffrey A. Jones, MD, MPH, Kami Maddocks, MD, John C. Byrd, MD

Blood (2013) 122 (21): 1321.

https://doi.org/10.1182/blood.V122.21.1321.1321

Published: 2013

Journal Articles

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

Deborah M Stephens, DO, Amy Stark, MAS, Jeffrey A. Jones, MD, MPH, Jennifer A. Woyach, MD, Kami Maddocks, Samantha M. Jaglowski, MD, MPH, Leslie A. Andritsos, MD, Joseph M. M. Flynn, DO, MPH, Michael R. Grever, MD, Gerard Lozanski, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, Ph.D, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 2872.

https://doi.org/10.1182/blood.V122.21.2872.2872

Published: 2013

Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study

Susan O'Brien, MD, Richard R. Furman, MD, Nathan Fowler, MD, Steven E. Coutre, MD, Jeff P. Sharman, MD, Kristie A. Blum, MD, Jan A. Burger, MD, PhD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, PhD, Emiliano Mugnaini, MD, Ian Flinn, MD, PhD, Ranjana H. Advani, MD, Kathryn S. Kolibaba, MD, Yun Shaw, Fong Clow, ScD, Danelle F. James, MD, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2013) 122 (21): 4163.

https://doi.org/10.1182/blood.V122.21.4163.4163

Published: 2013

Journal Articles

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Joseph M. M. Flynn, DO, MPH, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, MPH, Amy J. Johnson, PhD, Kami Maddocks, MD, Elizabeth Wiley, Karen Small, BSN, Eun Kyung Im, MD, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD, Honghong Zhou, PhD

Blood (2013) 122 (21): 871.

https://doi.org/10.1182/blood.V122.21.871.871

Published: 2013

NARROW

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Analysis of Healthcare Provider Practice Patterns from Individual Patient Cases Entered into an Online Treatment Decision Tool for Chronic Lymphocytic Leukemia (CLL)

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Assessment Of Hypersensitivity Reactions and Feasibility Of a 60 Minute Rapid Infusion Rituximab Protocol At a Comprehensive Cancer Center

B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo

Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients

Prognostic Significance Of Cytogenetic Complexity and Del(17p) At Diagnosis Of Chronic Lymphocytic Leukemia (CLL)

Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only